MX2021015319A - Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos. - Google Patents
Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos.Info
- Publication number
- MX2021015319A MX2021015319A MX2021015319A MX2021015319A MX2021015319A MX 2021015319 A MX2021015319 A MX 2021015319A MX 2021015319 A MX2021015319 A MX 2021015319A MX 2021015319 A MX2021015319 A MX 2021015319A MX 2021015319 A MX2021015319 A MX 2021015319A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- pyrazolopyrimidine
- sulphone
- jak kinase
- inhibitors based
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title 1
- 102000015617 Janus Kinases Human genes 0.000 abstract 1
- 108010024121 Janus Kinases Proteins 0.000 abstract 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019091712 | 2019-06-18 | ||
| US202063035381P | 2020-06-05 | 2020-06-05 | |
| PCT/US2020/037853 WO2020257145A1 (en) | 2019-06-18 | 2020-06-16 | Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015319A true MX2021015319A (es) | 2022-04-07 |
Family
ID=71575774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015319A MX2021015319A (es) | 2019-06-18 | 2020-06-16 | Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11453671B2 (https=) |
| EP (1) | EP3986901A1 (https=) |
| JP (1) | JP7657740B2 (https=) |
| KR (1) | KR20220024405A (https=) |
| CN (1) | CN114008051B (https=) |
| AU (1) | AU2020297415A1 (https=) |
| BR (1) | BR112021025618A2 (https=) |
| CA (1) | CA3140024A1 (https=) |
| CL (1) | CL2021003341A1 (https=) |
| CO (1) | CO2022000118A2 (https=) |
| CR (1) | CR20210661A (https=) |
| IL (1) | IL288957A (https=) |
| MA (1) | MA56518A (https=) |
| MX (1) | MX2021015319A (https=) |
| PE (1) | PE20220577A1 (https=) |
| PH (1) | PH12021552998A1 (https=) |
| TW (1) | TW202115068A (https=) |
| WO (1) | WO2020257145A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202115069A (zh) | 2019-06-18 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途 |
| KR102767443B1 (ko) * | 2022-04-14 | 2025-02-12 | 한국화학연구원 | 퀴녹살린 카르복스아마이드 유도체 및 이를 유효성분으로 포함하는 교모세포종의 예방 또는 치료용 약학적 조성물 |
| KR20250011137A (ko) | 2022-05-11 | 2025-01-21 | 피아이 인더스트리스 엘티디. | 바이사이클릭 화합물 및 해충 방제제로서 이의 용도 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| US6034057A (en) | 1995-07-06 | 2000-03-07 | Zeneca Limited | Peptide inhibitors of fibronectine |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| DE60214428T2 (de) | 2001-12-20 | 2007-09-20 | Bayer Healthcare Ag | 1, 4-dihydro-1, 4-diphenylpyridin-derivate |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| CA2676665A1 (en) * | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | Modulators of mitotic kinases |
| CN101616921A (zh) * | 2007-01-30 | 2009-12-30 | 比奥根艾迪克Ma公司 | 1-H-吡唑并(3,4b)嘧啶衍生物及其作为有丝分裂激酶调节剂的用途 |
| CN102131389A (zh) | 2008-06-20 | 2011-07-20 | 健泰科生物技术公司 | 三唑并吡啶jak抑制剂化合物和方法 |
| EP2348860B1 (en) | 2008-10-31 | 2015-05-27 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| AP2015008433A0 (en) | 2012-11-09 | 2015-05-31 | Jacobus Pahrmaceutical Company Inc | Heteroaryl derivatives and uses thereof |
| JP2017516850A (ja) | 2014-05-23 | 2017-06-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｊａｋ阻害剤である５−クロロ−２−ジフルオロメトキシフェニルピラゾロピリミジン化合物 |
| TW201720828A (zh) * | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| JP6936236B2 (ja) * | 2016-02-18 | 2021-09-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 治療化合物、組成物及びその方法の使用 |
| CR20190310A (es) | 2016-12-29 | 2019-08-21 | Hoffmann La Roche | Compuestos de pirazolopirimidina y métodos de uso de los mismos |
| JP2020510061A (ja) | 2017-03-14 | 2020-04-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ピラゾロクロロフェニル化合物、組成物及びその使用方法 |
| CN110678467B (zh) * | 2017-05-22 | 2023-06-13 | 豪夫迈·罗氏有限公司 | 治疗化合物和组合物及其使用方法 |
| MX387969B (es) | 2017-05-22 | 2025-03-19 | Hoffmann La Roche | Composiciones y compuestos terapéuticos, y métodos para su uso. |
| EP3740488A1 (en) * | 2018-01-15 | 2020-11-25 | F. Hoffmann-La Roche AG | Pyrazolopyrimidine compounds as jak inhibitors |
| AU2020210455B2 (en) * | 2019-01-25 | 2023-02-02 | Beijing Scitech-Mq Pharmaceuticals Limited | Acylamino bridged heterocyclic compound, and composition and application thereof |
| TW202115069A (zh) | 2019-06-18 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途 |
| EP3986899A1 (en) | 2019-06-18 | 2022-04-27 | F. Hoffmann-La Roche AG | Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof |
-
2020
- 2020-06-16 PH PH1/2021/552998A patent/PH12021552998A1/en unknown
- 2020-06-16 BR BR112021025618A patent/BR112021025618A2/pt not_active Application Discontinuation
- 2020-06-16 WO PCT/US2020/037853 patent/WO2020257145A1/en not_active Ceased
- 2020-06-16 AU AU2020297415A patent/AU2020297415A1/en not_active Abandoned
- 2020-06-16 KR KR1020227000044A patent/KR20220024405A/ko not_active Ceased
- 2020-06-16 JP JP2021574283A patent/JP7657740B2/ja active Active
- 2020-06-16 CN CN202080044750.2A patent/CN114008051B/zh active Active
- 2020-06-16 CR CR20210661A patent/CR20210661A/es unknown
- 2020-06-16 PE PE2021002182A patent/PE20220577A1/es unknown
- 2020-06-16 TW TW109120272A patent/TW202115068A/zh unknown
- 2020-06-16 MX MX2021015319A patent/MX2021015319A/es unknown
- 2020-06-16 CA CA3140024A patent/CA3140024A1/en active Pending
- 2020-06-16 MA MA056518A patent/MA56518A/fr unknown
- 2020-06-16 US US16/902,499 patent/US11453671B2/en active Active
- 2020-06-16 EP EP20739492.5A patent/EP3986901A1/en active Pending
-
2021
- 2021-12-13 IL IL288957A patent/IL288957A/en unknown
- 2021-12-14 CL CL2021003341A patent/CL2021003341A1/es unknown
-
2022
- 2022-01-12 CO CONC2022/0000118A patent/CO2022000118A2/es unknown
- 2022-08-24 US US17/821,851 patent/US20230016791A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200399275A1 (en) | 2020-12-24 |
| JP7657740B2 (ja) | 2025-04-07 |
| PE20220577A1 (es) | 2022-04-20 |
| AU2020297415A1 (en) | 2022-01-06 |
| CN114008051A (zh) | 2022-02-01 |
| WO2020257145A1 (en) | 2020-12-24 |
| PH12021552998A1 (en) | 2023-08-14 |
| CO2022000118A2 (es) | 2022-01-28 |
| CN114008051B (zh) | 2024-08-13 |
| US11453671B2 (en) | 2022-09-27 |
| IL288957A (en) | 2022-02-01 |
| KR20220024405A (ko) | 2022-03-03 |
| JP2022537964A (ja) | 2022-08-31 |
| TW202115068A (zh) | 2021-04-16 |
| US20230016791A1 (en) | 2023-01-19 |
| CR20210661A (es) | 2022-02-11 |
| MA56518A (fr) | 2022-04-27 |
| EP3986901A1 (en) | 2022-04-27 |
| CL2021003341A1 (es) | 2022-07-22 |
| BR112021025618A2 (pt) | 2022-02-01 |
| CA3140024A1 (en) | 2020-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021016594A2 (es) | Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| JOP20230277A1 (ar) | مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز (pi3k) لعلاج الأمراض | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| JOP20220131A1 (ar) | مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة | |
| MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
| GEP20227433B (en) | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | |
| PH12019502601A1 (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| PH12015500666A1 (en) | Pyrazolopyrimidine jak inhibitor compounds and methods | |
| WO2017089390A8 (en) | Janus kinases inhibitors, compositions thereof and use thereof | |
| EA201792116A1 (ru) | Ингибитор янус-киназы | |
| MX2020010805A (es) | Inhibidores de bcl6. | |
| WO2014106800A3 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors | |
| BR112021026682A2 (pt) | Compostos e métodos para inibir eif4e | |
| JOP20190130A1 (ar) | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) | |
| MX2021015319A (es) | Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos. | |
| SA523451700B1 (ar) | (pi3k) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز لعلاج السرطان | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| MX2022008627A (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas. | |
| JOP20220227A1 (ar) | مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة | |
| MX2022004878A (es) | Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. | |
| JOP20230275A1 (ar) | معدلات trex1 | |
| EA202191482A1 (ru) | Другие гетероароматические соединения, обладающие активностью против rsv | |
| GEAP202516217A (en) | Compounds and compositions as sppl2a inhibitors |